Community-acquired Pneumonia Clinical Trial
Official title:
A Randomized, Controlled Clinical Trial on the Effect of Protein Supplement on Lean Body Mass in Patients With Community Acquired Pneumonia
The purpose of this clinical trial is to reduce the patient's loss of lean body mass by
protein supplementation during hospitalization and 60 days after hospital discharge. Also,
the study aims to reduce the risk of readmission to the hospital due to relapse or
complications and thereby improving the overall health for the patients.
The intervention group will receive protein supplementation during hospitalization and after
discharge, while the control group will continue their normal diet.
Infections are globally the biggest cause of mortality. In Denmark community acquired
pneumonia is one of the most common causes for infections in patients. Mortality in pneumonia
has been stable high over the past 10 years. Therefore, it is relevant to look at improving
the prognosis of these patients. After a longer period of hospitalization, patients generally
have a poor condition with loss of body weight and lean body mass. Hereafter, patients must
often undergo a longterm rehabilitation period and they become inactive and fatigue.
This is a threat for the patients, due to the fact that there is a higher risk of
complications and readmissions.
Proteins are the body's building blocks. Thus, supplementing patients with a daily higher
protein content, it is believed to reduce their loss of lean body mass, and thereby reduce
the total loss of body weight as well. Protein supplementation together with vitamin- and
mineral supplementation is thought to improve all these health risk markers for the patients.
Methods:
Inclusion: 40 men and women >60 years hospitalized with community acquired pneumonia
Intervention: The patients will be randomized to either the control- or intervention group.
They will receive the same treatment and care, the only difference is that the patients in
the intervention group will receive protein- and vitamin supplementation.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05722938 -
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
|
Phase 3 | |
| Terminated |
NCT04972318 -
Two Different Ventilatory Strategies in Acute Respiratory Distress Syndrome Due to Community-acquired Pneumonia
|
N/A | |
| Recruiting |
NCT06065618 -
Characteristics of Hospitalized Patients With Community-acquired Pneumonia
|
||
| Not yet recruiting |
NCT03675178 -
Clinical Study of Anerning Particle for the Treatment of Childhood Community-acquired Pneumonia
|
Phase 4 | |
| Not yet recruiting |
NCT04166110 -
Antibiotic Therapy In Respiratory Tract Infections
|
N/A | |
| Completed |
NCT02380352 -
Short-course Antimicrobial Therapy for Paediatric Respiratory Infections
|
Phase 4 | |
| Completed |
NCT01671280 -
Drug Use Investigation Of Azithromycin IV For Community-Acquired Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan)
|
N/A | |
| Completed |
NCT02555852 -
Proton Pump Inhibitors and Risk of Community-acquired Pneumonia
|
N/A | |
| Recruiting |
NCT00752947 -
Efficacy and Safety Trial to Assess Moxifloxacin in Treating Community-Acquired Pneumonia (CAP) With Aspiration Factors
|
Phase 4 | |
| Completed |
NCT00140023 -
Azithromycin Microspheres in Patients With Low Risk Community Acquired Pneumonia
|
Phase 3 | |
| Recruiting |
NCT04089787 -
Shortened Antibiotic Treatment of 5 Days in Community-Acquired Pneumonia
|
Phase 4 | |
| Completed |
NCT05356494 -
Postural Drainage and PEP Technique in Community Acquired Pneumonia
|
N/A | |
| Completed |
NCT05133752 -
Oral Nemonoxacin in Treating Elderly Patients With CAP
|
Phase 4 | |
| Not yet recruiting |
NCT06291012 -
Stopping Pneumonia Antibiotherapy Regimen Early
|
Phase 4 | |
| Recruiting |
NCT05002192 -
A Retrospective, Real-world Study of ELP Used in the Expectorant Treatment of Community-acquired Pneumonia
|
||
| Completed |
NCT03452826 -
Combined Use of a Respiratory Broad Panel mPCR and Procalcitonin to Reduce Duration of Antibiotics Exposure in Patients With Severe Community-Acquired Pneumonia
|
N/A | |
| Terminated |
NCT04071041 -
Effect of Albumin Administration in Hypoalbuminemic Hospitalized Patients With Community-acquired Pneumonia.
|
Phase 3 | |
| Completed |
NCT03474991 -
KIDS-STEP_Betamethasone Therapy in Hospitalised Children With CAP
|
Phase 3 | |
| Completed |
NCT01683487 -
Delayed Antibiotic Treatment in Community-acquired Pneumococcal Pneumonia.
|
Phase 4 | |
| Completed |
NCT01723644 -
Clinical Reassessment Versus Procalcitonin in Order to Shorten Antibiotic Duration in Community-acquired Pneumonia
|
N/A |